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Abstract: To evaluate whether obese patients with a binge eating
disorder (BED) have an altered metabolic and inflammatory profile
related to their eating behaviors compared with non-BED obese.
A total of 115 White obese patients consecutively recruited under-
went biochemical, anthropometrical evaluation, and a 75-g oral glucose
tolerance test. Patients answered the Binge Eating Scale and were
interviewed by a psychiatrist. The patients were subsequently divided
into 2 groups according to diagnosis: non-BED obese (n¼ 85) and BED
obese (n¼ 30). Structural equation modeling analysis was performed to
elucidate the relation between eating behaviors and metabolic and
inflammatory profile.
BED obese exhibited significantly higher percentages of altered
eating behaviors, body mass index (P<0.001), waist circumference
(P<0.01), fat mass (P<0.001), and a lower lean mass (P<0.001)
when compared with non-BED obese. Binge eating disorder obese also
had a worse metabolic and inflammatory profile, exhibiting significantly
lower high-density lipoprotein cholesterol levels (P<0.05), and higher
levels of glycated hemoglobin (P<0.01), uric acid (P<0.05), eryth-
rocyte sedimentation rate (P<0.001), high-sensitive C-reactive protein
(P<0.01), and white blood cell counts (P<0.01). Higher fasting
insulin (P<0.01) and higher insulin resistance (P<0.01), assessed
by homeostasis model assessment index and visceral adiposity index
(P<0.001), were observed among BED obese. All differences
remained significant after adjusting for body mass index. No significant
differences in fasting plasma glucose or 2-hour postchallenge plasmaMatteo Aloi, PsD, azio, MD,
anco Arturi, MD, PhD
Binge eating disorder obese exhibited an unfavorable metabolic and
inflammatory profile, which is related to their characteristic eating
habits.
(Medicine 94(52):e2098)
Abbreviations: ADA = American Diabetes Association, BED =
binge eating disorder, BED-CI = Binge Eating Disorder-Clinical
Interview, BES = Binge Eating Scale, BMI = body mass index,
BP = blood pressure, CFI = comparative fit index, CMIN/DEF =
ratio of x2 and degree of freedom, CVD = cardiovascular disease,
ED = eating disorder, ESR = erythrocyte sedimentation rate,
GLM = general linear model, HDL = high-density lipoprotein,
HOMA-IR = homeostasis model assessment index, hs-CRP = high-
sensitive C-reactive protein, IL-6 = interleukin-6, LDL = low-
density lipoprotein, OGTT = oral glucose tolerance test, RMSEA =
root mean square error of approximation, SEM = structural
equation modeling, T2DM = type 2 diabetes mellitus, TLI =
Tucker–Lewis index, TNF-a = tumor necrosis factor-a.
INTRODUCTION
O besity is the second cause of death in the world and hasreached epidemic proportions in recent years.1 The World
Health Organization estimates that there are over 1 billion
overweight adults globally, 300 million of whom are obese.1
Obesity is a chronic disease and is associated with numerous
comorbidities, including type 2 diabetes mellitus (T2DM),
cardiovascular disease, hypertension, and dyslipidemia. More-
over, obesity is a risk factor for major causes of morbidity and
mortality2,3 and increasing evidence shows that a binge eating
disorder (BED) affects a subset of obese patients.4,5
Binge eating disorder is a psychiatric disorder character-
ized by recurrent episodes of binge eating (ie, eating large
amounts of food) and is associated with a loss of control and
significant distress in the absence of the regular compensatory
weight-reducing behaviors commonly observed among patients
with bulimia nervosa.4 The prevalence of BED in the normal
adult population varies from 2% to 5%, but this proportion rises
up to 50% among obese adults seeking weight reduction.6
European data indicate that the general prevalence of BED
in Italy is approximately 1.12% (0.26% among men and 1.92%
among women).7 Binge eating disorder is strongly linked with
obesity and binge eating per se is linked with a high burden of
metabolic risk factors in the general population.5,8 Studies on
obese patients with BED suggest an increased risk for the
metabolic syndrome both in adults and adolescents.9,10 Several
studies showed a higher prevalence of BED in young and
overweight patients with T2DM.11,12 Furthermore, BED isr glycemic control and higher rates of
in adolescents and adults with type 1
ting disorder and binging behaviors are
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associated with poorer response to weight loss therapy.5,9 A few
studies, however, have assessed the metabolic profile of BED
obese without T2DM and no data are available on the relation
between different eating behaviors and the metabolic profile of
these patients.
Growing evidence suggests that obesity is associated with
a chronic inflammatory state. Indeed, a body of studies suggests
the presence of an overall, low-grade inflammation in obesity,
with increased levels of several circulating factors, such as high-
sensitive C-reactive protein (hs-CRP), tumor necrosis factor-a,
interleukin-6, and other biologic markers of inflammation.15
Conversely, a reduction in body weight is accompanied by a
decrease or even a normalization of these inflammatory mar-
kers, which are known to have a causal relationship with obesity
and its comorbidities, such as insulin resistance, T2DM, and
cardiovascular risk.15 Low-grade inflammation is strongly
linked with obesity15 but, to our best knowledge, no data are
available on the possible differences regarding the inflamma-
tory profile between obese patients with and without BED.
The aim of this study was to evaluate whether obese
patients with BED and without T2DM have a different meta-
bolic and inflammatory profile related to their eating behaviors
compared with non-BED obese. We also wished to test the
hypothesis that the characteristic eating patterns of BED obese
lead to an altered metabolic and inflammatory profile when
compared with non-BED obese.
METHODS
Study Participants
A total of 115 White obese patients without T2DM were
consecutively recruited in this cross-sectional study at the Depart-
ment of Medical and Surgical Sciences of the University ‘‘Magna
Graecia’’ of Catanzaro (Italy) from December 2013 to December
2014. Patients were enrolled according to the following eligibility
criteria: aged between 20 and 65 years, body mass index (BMI)
>30 kg/m2 and the ability to answer a self-reporting question-
naire. Exclusion criteria were as follows: pregnancy or having
recently given birth, previous diagnosis of diabetes mellitus,
known inflammatory disease, a history of malignant disease or
pathologies, or drugs able to modify glucose metabolism.
After 12-hour fasting, a venous blood sample was drawn for
laboratory determinations and a 75 g oral glucose tolerance test
was performed with 0, 30, 60, 90, and 120 minutes of sampling
for plasma glucose and insulin for each patient. Glucose tolerance
status was defined on the basis of body mass index according to
the American Diabetes Association criteria.16
Patients underwent anthropometrical evaluation, wearing
light indoor clothing, and no shoes, with a standing height to the
nearest 0.1 cm and a body weight to the nearest 0.1 kg at 8.00
AM. Height and weight were measured using a portable stadi-
ometer (Seca 220, GmbH & Co., Hamburg, Germany) and a
balance scale (Seca 761, GmbH & Co., Hamburg, Germany);
then, their BMI (kg/m2) was calculated. In addition, waist and
hip circumference were measured, and body composition was
estimated by bioelectrical impedance. Blood pressure was
measured using a calibrated manual sphygmomanometer and
a stethoscope on the brachial artery at the antecubital area of the
left elbow with patients supine after 5 minutes of rest.
The Hospital Ethical Committee (Comitato Etico Azienda
Ospedaliera ‘‘Mater Domini’’) approved protocol in September
Succurro et al2013, and written informed consent was obtained from all
patients. All the investigations were performed in accordance
with the principles of the Declaration of Helsinki.
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Patients answered the Binge Eating Scale (BES).17 Binge
Eating Scale is an easy to administer test with adequate internal
consistency and validity. It has been widely used in research
either to measure binge eating severity in the nonpurge binge
eating population or to determine whether potential research
patients meet the inclusion criteria for binge eating. Binge
Eating Scale is made up of 16 items describing the behavioral
manifestations, feelings, and cognitions associated with binge
eating. Each item consists of 4 statements that reflect a range of
severity from which patients choose the 1 that best describes
their perceptions and feelings about their eating behavior. A
total BES score <17 indicates unlikely BED, a 17 to 27 score
possible BED and values >27 probable BED.
Psychiatric researchers with adequate training in the field
of eating disorders interviewed each patient a week later. The
interviewers examined each patient by means of the Structured
Clinical Interview for DSM-IVAxis I Disorders18 and the Binge
Eating Disorder-Clinical Interview19 to respectively assess/
confirm the diagnosis of BED and to deepen understanding
of their eating behaviors (ie, night eating, postdinner eating,
social eating, sweet eating, emotional eating, grazing, craving
for carbohydrates, and hyperphagia) and exercise habits.
The clinical interview through the Structured Clinical
Interview for DSM-IVAxis I Disorders confirmed the diagnosis
of BED for all the obese patients with BES scores17. No BED
diagnosis was confirmed among patients with BES< 17.
According to the diagnosis of the BED, the patients were
divided into 2 groups: non-BED obese patients (n¼ 85) and
BED-obese patients (n¼ 30).
Laboratory Determinations
Plasma glucose, total and high-density lipoprotein (HDL)
cholesterol, triglycerides, and uric acid concentrations were
measured by enzymatic methods (Roche Diagnostics, Man-
nheim, Germany). HbA1c was measured with high-perform-
ance liquid chromatography using a National Glycohemoglobin
Standardization Program certified automated analyzer and
IFCC (Adams HA-8160 HbA1C analyzer, Menarini, Italy;
normal reference range, 4.3%–5.9%).
Plasma insulin concentration was determined by a chemi-
luminescence-based assay (IMMULITE, Siemens Healthcare,
Italy). High-sensitivity C reactive protein levels were measured
by an automated instrument (CardioPhase hsCRP, Milan, Italy).
The erythrocyte sedimentation rate (ESR) was measured auto-
matically by the stopped-flow technique in a capillary micro-
photometer (Alifax Test 1 System Polverara, Italy). All others
metabolites were measured by standard methods. Insulin resist-
ance was estimated by the homeostasis model assessment
(HOMA-IR) index, calculated from the fasting glucose, and
insulin concentrations according to the following formula (fast-
ing insulin fasting glucose)/22.5.20 The visceral adiposity
index (VAI) was calculated using the formulas proposed by
Amato et al21 for men, VAI¼ [WC/36.58þ (1.89BMI)]
(TG/0.81) (1.52/HDL) and for women, VAI¼ [WC/
39.68þ (1.88BMI)] (TG/1.03) (1.31/HDL).
Statistical Analysis
Data were analyzed using the Statistical Package for the
Social Science, version 21.0 (SPSS Inc., Chicago, IL). Variables
Medicine  Volume 94, Number 52, December 2015with skewed distribution, including triglyceride, hsCRP, ESR,
white blood cell (WBC), and fasting insulin were natural log
transformed for statistical analyses. Continuous data are
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were considered adequate and 0.05 or less very good. The ratioexpressed as means SD. Categorical variables were compared
by x2 test. Anthropometric and metabolic differences between
groups were tested after adjusting for age, sex, and BMI using a
general linear model. A P value <0.05 was considered statisti-
cally significant. Cohen’s effect sizes (ES) were calculated for
all significant findings, with values (negative or positive) of 0.2,
0.6, 1.2, and >1.2 indicating trivial, small, moderate, and large
ES, respectively.22
The structural equation modeling using maximum like-
lihood estimation was conducted by means of SPSS/AMOS
21.0 to test for the validity of the hypothesized model. Structural
equation modeling is a method that allows the simultaneous
estimation of all relationships between observed (manifest or
unmeasured) and unobserved (or latent) variables of a model. It
is graphically represented with observed variables enclosed by
rectangles and latent variables by circles. An assumed causal
path between 2 variables is shown by a directed edge (single-
headed arrow). Path coefficients on the edges are partial stan-
dardized regression coefficients, which measure the effect of 1
variable on another, while controlling for all other variables
prior in the model; all coefficients show a positive association,
Medicine  Volume 94, Number 52, December 2015but those with a minus sign indicate a negative association.
Model fit was evaluated using the comparative fit index (CFI),
the Tucker–Lewis incremental fit index (TLI), and root mean
TABLE 1. Comparison of Anthropometrical and Laboratory Char
Non-BED Obese BED O
Mean SD Mean
N (man/woman)a 85 (32/53) 30
Age, y 41.8 12.8 36.8
BMI (kg/m2) 37.2 6.2 43.7
Waist circumference (cm) 115.8 14.4 125.2
Hip (cm) 122.0 12.1 132.1
Waist/hip ratio 0.9 0.1 1.0
Fat mass (%) 37.5 8.2 48.4
Lean mass (%) 62.5 8.2 53.6
Systolic blood Pressure (mm Hg) 123.4 13.9 120.7
Diastolic blood Pressure (mm Hg) 80.3 10.0 77.5
Cholesterol total (mg/dL) 190.0 39.5 192.7
HDL cholesterol (mg/dL) 49.5 13.4 44.1
LDL cholesterol (mg/dL) 124.8 33.9 129.2
Triglycerides (mg/dL) 135.0 87.3 131.2
HbA1c (%) 5.5 0.6 5.8
Uric acid (mg/dL) 5.3 1.3 11.1
ESR (mm/h)

11.8 10.6 23.0
hs-CRP (mg/L)

4.2 4.9 7.9
White blood cells (103/mL) 6848.5 1737.3 7923.5
Fasting glucose (mg/dL) 96.2 16.4 94.4
2-hour glucose (mg/dL) 129.7 38.6 128.6
Fasting insulin (mU/mL)

20.4 11.4 40.0
HOMA-IR 4.9 3.1 11.6
VAI 131.8 89.1 231.8
Categorical variables are indicated with (a) and were compared by x2 test. C
log transformed for statistical analyses are indicated with (

). Comparisons b
column of P values refer to results of analysis without adjustment. Second col
age. Third column of P values refer to results after analyses with adjustme
BMI¼ body mass index, ESR¼ erythrocyte sedimentation rate, HDL¼
index, hs-CRP¼ high-sensitive C-reactive protein, LDL¼ low-density lipo
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.square error of approximation (RMSEA). The magnitudes of
these indices were evaluated according to the recommendations
of Hu and Bentler.23 For CFI and TLI, values of 0.90 and above
were considered adequate, whereas values of 0.95 or abovewere
considered very good; for RMSEA values of 0.08 and below
Metabolic and Inflammatory Profile in Binge Eating Disorder Obeseof x2 and degree of freedomwas also evaluated, considering that
values below 3.0 are good and those below 2.0 are very good.
RESULTS
Table 1 shows the anthropometrical characteristics and
laboratory findings for the 2 study groups. There were no
differences in age and sex between BED and non-BED obese.
Binge eating disorder obese exhibited significantly higher BMI,
waist circumference, hip circumference, waist/hip ratio, and fat
mass, and a lower lean mass as compared with non-BED obese;
these differences remained significant after adjusting for BMI
(Table 1). There were no differences between the groups in
blood pressure, total cholesterol, low-density lipoprotein cho-
lesterol, triglycerides. Binge eating disorder obese had a worse
metabolic and inflammatory profile, exhibiting significantly
lower HDL cholesterol and higher levels of HbA1c, uric acid,
ESR, hs-CRP, and WBC and all these differences remained
acteristics Between Groups
bese Unadjusted
Estimates
Adjusted
Estimates for
Age and Sex
Adjusted Estimates
for BMI
SD P P P
(8/22) NS  
12.7 NS  
6.8 <0.001 <0.001 
11.7 <0.01 <0.001 <0.001
14.0 <0.001 <0.05 <0.001
0.1 <0.001 <0.001 0.001
10.1 <0.001 <0.001 <0.001
8.6 <0.001 <0.001 <0.001
12.1 NS <0.001 <0.001
9.8 NS <0.001 <0.001
27.6 NS NS NS
10.6 <0.05 <0.001 0.001
23.2 NS <0.05 <0.05
51.3 NS <0.01 <0.05
0.7 <0.01 0.001 0.001
24.7 <0.05 <0.05 0.05
13.3 <0.001 <0.001 <0.001
7.3 <0.01 <0.05 <0.001
2094.2 <0.01 <0.01 <0.001
20.9 NS <0.01 0.001
53.6 NS <0.01 <0.05
53.0 <0.01 0.001 <0.01
22.7 <0.01 <0.01 <0.01
164.9 <0.001 <0.01 <0.01
ontinuous data are expressed as meansSD. Variables that were natural
etween the 2 groups were performed using a general linear model. First
umn of P values refer to results after analyses with adjustment for sex and
nt for BMI.
high-density lipoprotein, HOMA-IR¼ homeostasis model assessment
protein, VAI¼ visceral adiposity index.
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Succurro et al Medicine  Volume 94, Number 52, December 2015significant after adjusting for BMI (Table 1). Binge eating
disorder obese also exhibited significantly higher levels of
fasting plasma insulin and higher degree of insulin resistance
as assessed by HOMA-IR index and VAI compared with non-
BED obese; similarly, differences remained significant after
adjusting for BMI. No significant differences were found in
fasting glucose and 2-hour postload plasma glucose. Blood
pressure, low-density lipoprotein cholesterol, triglycerides,
fasting glucose, and 2-hour postload plasma glucose were
statistically significant after adjusting for BMI.
Regarding eating habits, BED obese revealed significantly
FIGURE 1. Eating behaviors in binge eating disorder and non-binhigher percentages of grazing, emotional eating, night eating,
sweet eating, and craving for carbohydrates than non-BED
obese (Figure 1).
Body  
weight  
homaIR 
Inflammatory
indexes 
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Model Fit Summary:  
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FIGURE 2. Path diagram showing the relation between eating b
BED¼binge eating disorder, CFI¼ comparative fit index, CH¼ cr
ESR¼ erythrocyte sedimentation rate; RMSEA¼ root mean square e
adiposity index.
4 | www.md-journal.comStructural equation modeling was conducted to test the
hypothesis that altered eating behaviors affect anthropome-
trical, metabolic, and inflammatory variables. The model
achieved goodness-of-fit: x2¼ 69.755; P¼0.261; ratio of
x2 and degree of freedom¼ 1.107; CFI¼0.980; TLI¼0.970;
0.970; and RMSEA¼0.032. In our model, altered eating
behaviors (ie, night eating, sweet eating, craving for carbo-
hydrates, emotional eating, and grazing) showed an indirect
effect on waist circumference mediated by the diagnosis of
BED and body weight; waist circumference had an indirect
effect on HbA1c mediated by insulin resistance assessed
*p<.05; ***p<.001
eating disorder obese patients.either by HOMA-IR or VAI; and VAI had a direct effect
on the inflammatory indexes (ie, ESR, hs-CRP, and uric acid;
Figure 2).
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DISCUSSION
In this study, we showed an unfavorable metabolic and
inflammatory profile in obese patients with BED as compared
with non-BED obese.
Notably, we reported, for the first time that BED obese,
exhibited a worse anthropometric and metabolic profile in
relation to their different eating behaviors, as compared with
non-BED obese. There are several potential mechanisms by
which binge eating may cause or contribute to obesity. The
characteristic eating patterns of BED individuals seem to be
associated with specific metabolic abnormalities of obesity. For
example, the ingestion of fewer but larger meals has adverse
metabolic consequences than the ingestion of frequent, small
meals, including increase in fasting glucose, insulin secretion,
serum lipids, and deterioration of glucose tolerance.10,24 Eating
rapidly results in elevated serum lipids, higher waist-hip cir-
cumference ratio, and liver steatosis.25 The mechanism(s)
underlying the relationship between eating rate and fatty liver
are not known. As reported by Kral et al,25 it is hypothesized
that the enhance and rapid glucose absorption, mediated by a
brisk insulin response via cephalic phase release, an incretin
effect and rapid intestinal handling, causes fatty infiltration of
the liver via glucose toxicity. Alone or in conjunction with rapid
absorption of lipid, glucose and insulin increases may lead to
insulin resistance and metabolic syndrome with central/visceral
fat distribution and dyslipidemia. Besides, increased insulin
levels induced by binging may contribute to increased hunger.26
In fact, BED patients eat significantly more than do non-BED
obese during the stimulation of a binge eating episode.27
Despite the relation between specific metabolic alterations
and these eating features of BED individuals (ie, speed and
amount), little is known about the metabolic consequences of
the other eating habits typically observed in BED individuals
(eg, craving for carbohydrates, sweet eating, grazing, or
emotional eating).
Herein, we provide evidence that BED obese showed a
higher frequency of altered eating behaviors (ie, binging,
grazing, emotional eating, sweet eating, and craving for carbo-
hydrates) than non-BED obese.
We did not observe a significant difference in binge eating
frequency between BED and non-BED obese patients. The
symptom ‘‘binge’’ does not directly imply with the diagnosis
of BED. ‘‘Binge eating’’ is a behavior marked by consumption
of a large amount of food within a short period of time with the
sense of loss of control. But to fulfill the diagnosis of BED,4 the
patient needs to have other symptoms, such as eating quickly,
eating until feeling full, eating even if not hungry, eating alone
for embarrassment and/or feeling disgusted, depressed, or guilty
for overeating. So binge is a characteristic symptom but not an
exclusive symptom of patients with BED. On the contrary,
DSM-IV requires that binges occur at least 2 days a week for 6
months, so many obese patients could not satisfy the criteria of
frequency while still binging. As binging becomes a distraction
related to aversive emotional states, BED obese tend more
frequently to eat in response to emotions.28 Our results are in
agreement with previous data showing that emotional eating is
associated with the preference for sweet foods and that BED
obese crave carbohydrates more than fats, compared with non-
BED obese.29 As previously reported, grazing, another dysfunc-
tional eating behavior that consists of smaller, subjective epi-
Medicine  Volume 94, Number 52, December 2015sodes of overeating, was significantly more evident among BED
obese as compared with non-BED obese. We postulate that the
compensatory pattern, demonstrated in healthy lean patients,
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.could be impaired in patients who are already obese and have
chronic binge habits. These habits could be responsible, in
association with obesity, for the worse metabolic profile
observed in BED obese.30 Accordingly, we found that BED
obese exhibited a significantly higher BMI, fat mass, fasting
insulin levels, HOMA-IR index, and HbA1c when compared
with non-BED obese. Moreover, among BED obese, we found
an increased abdominal circumference, an indirect index of
visceral adiposity and an increased VAI, an indicator of a
dysfunction of adipose tissue.21,31,32 In obese patients, visceral
adipose tissue accumulation has been associated with an
increased production of free fatty acids, interleukin-6, tumor
necrosis factor-a, hs-CRP, and a decreased production of
adiponectin, each of which may contribute to insulin resistance.
It is known that these cytokines and chemokines activate
intracellular pathways that lead to the development of insulin
resistance, increasing the risk of T2DM.33 A previously study
demonstrated that women with BED had significantly reduced
plasma levels of adiponectin.34 Accordingly, it is conceivable
that increased visceral adiposity observed in BED obese may be
responsible for increased insulin resistance, estimated by the
HOMA-IR index.
Importantly, we observed that the BED obese showed
elevated inflammatory markers, such as hs-CRP, ESR, and
WBC counts. Several studies showed that chronic subclinical
inflammation is associated with T2DM, cardiovascular disease,
and patients at high risk of developing T2DM.35–39 Elevation in
hs-CRP is considered a marker of cardiovascular risk that has
also been correlated with insulin resistance.33 Increasing evi-
dence has shown that the accumulation of lipids in adipose
tissue and the expansion of fat mass determine the initiation of
the obesity-induced inflammatory process through the pro-
duction of proinflammatory cytokines and chemokines by the
fat tissue.33
All these differences remained significant after adjusting
for BMI. Our results, in line with Hudson et al,9 disagree with
Abraham et al.8 A possible explanation is that the research by
Hudson et al was drawn among obese patients, as in our case,
whereas Abraham et al used a large population-based cohort
comparing obese (most bingers) with overweight (most non-
bingers).
Moreover, we found, that BED obese showed higher uric
acid levels than non-BED obese did. Elevation in uric acid has
been associated with obesity and insulin resistance, all risk
factors for atherosclerosis, and T2DM.40 The prooxidant and
proinflammatory effects of uric acid that interfere with glucose
uptake may explain this association. Furthermore, hyperurice-
mia is frequently documented in patients with cardiovascular
diseases and with subclinical organ damage.41
Structural equation modeling analysis helps to explain the
relation between eating behaviors and metabolic impairment.
Night eating, sweet eating, grazing, emotional eating, and
craving for carbohydrates may lead to increased waist circum-
ference, an index of visceral adiposity, and insulin resistance,
which, in turn, may favor production of inflammatory mol-
ecules, and alteration in glucose metabolism. The mechanism(s)
by which the eating behaviors are able to induce an alteration of
metabolic profile and/or the inflammatory profile is not known.
It might represent a direct effect of binge eating, perhaps
because of the large amount of food ingested in typical eating
binges.42 Also, rapid consumption of large amounts of food can
Metabolic and Inflammatory Profile in Binge Eating Disorder Obeseincrease oxidative and inflammatory stress,43,44 and inflamma-
tory changes could represent an important causal pathway for
developing metabolic alterations. Alternatively, because BED
www.md-journal.com | 5
appears to be partially caused by genetic factors independent of
obesity,45–47 it is possible that these or other underlying non-
genetic factors might be responsible for these alterations.
The novelty of this article is that an eating disorder, namely
BED, and the related altered eating behaviors, can help to explain
an impaired metabolic and inflammatory profile in a group of
obese patients that could have an increased cardiometabolic risk.
Strengths of this study are the exclusion of patients with
T2DM or confounding disorders characterized by elevation in
inflammatory molecules, inclusion of both sexes, the accurate
anthropometric, metabolic, inflammatory and psychiatric
characterization, and the evaluation of eating behaviors.
The findings of this study, however, need to be interpreted
in light of some limitations. First, the current results derive from
a cross-sectional research with a small sample of obese patients.
Nevertheless, the sample included all obese patients that con-
secutively asked for weight reduction therapy in our depart-
ment. Furthermore, ES and fit indexes of structural equation
modeling demonstrated that the results were not influenced by
the sample size. A second limitation of the current study is that
we have evaluated insulin sensitivity by the HOMA-IR index.
Although the euglycaemic–hyperinsulinaemic clamp, which is
considered the gold standard method to measure insulin sensi-
tivity, may provide a more accurate estimate of insulin sensi-
tivity, it is time consuming and expensive, and is not feasible in
large-scale studies.
Despite the limitations, our findings may have important
clinical implications. The current study confirms and expands
the actual knowledge about the effects of specific dysfunctional
eating behaviors commonly observed among obese patients on
important metabolic and inflammatory alterations. All obese
patients should be assessed for BED and it can be done through
an easy tool, the BES. This could represent an important clinical
target to identify patients potentially at high risk for obesity,
T2DM, and/or cardiometabolic disease. Further research and
prospective studies, however, are needed to assess and evaluate
whether early detection and intervention for this specific dis-
order could have a positive prognostic impact on the long-term
outcome (eg, T2DM and/or cardiovascular risk) of this specific
group of obese patients seeking weight reduction.
ACKNOWLEDGMENTS
Authors are grateful to Antonio Jose´ Ruiz Moruno and
Carmelo Nobile for their technical support in performing the
statistical analysis.
REFERENCES
1. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–1209.
2. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an
independent risk factor for cardiovascular disease: a 26-year follow-
up of participants in the Framingham Heart Study. Circulation.
1983;67:968–977.
3. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and
mortality in a large prospective cohort of persons 50 to 71 years old.
N Engl J Med. 2006;355:763–778.
4. American Psychiatric Association. Diagnostic and Statistical Manual
of Mental Disorders. 4th ed. Washington, DC: Text Revision; 2000.
5. De Zwaan M. Binge eating disorder and obesity. Int J Obes Relat
Metab Disord. 2001;25:S51–S55.
Succurro et al6. Hudson JI, Hiripi E, Pope HG Jr et al. The prevalence and
correlates of eating disorders in the National Comorbidity Survey
Replication. Biol Psychiatry. 2007;61:348–358.
6 | www.md-journal.com7. Preti A, Vilagut GD, Alonso J, et al. The epidemiology of eating
disorders in six European countries: results of the ESEMeD-WMH
project. J Psychiatr Res. 2009;43:1125–1132.
8. Abraham TM, Massaro JM, Hoffmann U, et al. Metabolic character-
ization of adults with binge eating in the general population: the
Framingham Heart study. Obesity. 2014;22:2441–2449.
9. Hudson JI, Lalonde JK, Coit CE, et al. Longitudinal study of the
diagnosis of components of the metabolic syndrome in individuals
with binge-eating disorder. Am J Clin Nutr. 2010;91:1568–1573.
10. Blomquist KK, Milsom VA, Barnes RD, et al. Metabolic syndrome
in obese men and women with binge eating disorder: developmental
trajectories of eating and weight-related behaviors. Compr Psychia-
try. 2012;53:1021–1027.
11. Meneghini LF, Spadola J, Fiorez H. Prevalence and associations of
binge eating disorder in a multiethnic population with type 2
diabetes. Diabetes Care. 2006;29:2760.
12. Wilfley D, Berkowitz R, Goebel-Fabbri A, et al., TODAY Study
Group. Binge eating, mood, and quality of life in youth with type 2
diabetes. Diabetes Care. 2011;34:858–860.
13. Wing RR, Nowalk MP, Marcus MD, et al. Subclinical eating
disorders and glycemic control in adolescents with type I diabetes.
Diabetes Care. 1986;9:162–167.
14. Scheuing N, Bartus B, Berger G, et al., DPV Initiative; German
BMBF Competence Network Diabetes Mellitus. Clinical character-
istics and outcome of 467 patients with a clinically recognized
eating disorder identified among 52,215 patients with type 1
diabetes: a multicenter German/Austrian study. Diabetes Care.
2014;37:1581–1589.
15. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the
relationship between obesity, inflammation, and insulin resistance.
Eur Cytokine Netw. 2006;17:4–12.
16. American Diabetes Association. Diagnosis and classification of
diabetes mellitus. Diabetes Care. 2011;34:S62–S69.
17. Gormally J, Black S, Daston S. The assessment of binge eating
severity among obese persons. Addict Behav. 1982;7:47–55.
18. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the
Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I)
and Axis II Disorders (SCID II). Clin Psychol Psychoter.
2011;18:75–79.
19. Spitzer RL, Yanovsky SZ, Marcus MD. Binge Eating Clinical
Interview. Pittsburgh, PA: HaPI Record; 1994.
20. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model
assessment: insulin resistance and beta-cell function from fasting
plasma glucose and insulin concentrations in man. Diabetologia.
1985;28:412–419.
21. Amato MC, Giordano C, Galia M, et al., AlkaMeSy Study Group.
Visceral Adiposity Index: a reliable indicator of visceral fat function
associated with cardiometabolic risk. Diabetes Care. 2010;33:
920–922.
22. Cohen J. Statistical Power Analysis for the Behavioral Sciences.
Hillsdale, MI: Lawrence Erlbaum Associates Inc; 1988.
23. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance
structure analysis: conventional criteria versus new alternatives.
Struct Equ Modeling. 1999;6:1–55.
24. Taylor AE, Hubbard J, Anderson EJ. Impact of binge eating on
metabolic and leptin dynamics in normal young women. J Clin
Endocrinol Metab. 1999;84:428–434.
25. Kral JG, Buckley MC, Kissileff HR, et al. Metabolic correlates of
eating behavior in severe obesity. Int J Obes Relat Metab Disord.
Medicine  Volume 94, Number 52, December 20152001;25:258–264.
26. Stricker EM. Biological bases of hunger and satiety: therapeutic
implications. Nutr Rev. 1984;42:333–340.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
27. Sysko R, Devlin MJ, Walsh BT, et al. Satiety and test meal intake
among women with binge eating disorder. Int J Eat Disord.
2007;40:554–561.
28. Ramacciotti CE, Coli E, Marazziti D, et al. Therapeutic options for
binge eating disorder. Eat Weight Disord. 2013;18:3–9.
29. Meule A, Allison KC, Platte P. Emotional eating moderates the
relationship of night eating with binge eating and body mass. Eur
Eat Disord Rev. 2014;22:147–151.
30. Wadden TA, Foster GD, Letizia KA, et al. Metabolic, anthropo-
metric psychological characteristics of obese binge eaters. Int J Eat
Disord. 1993;1:17–25.
31. Zhang X, Shu X, Li H, et al. Visceral adiposity and risk of coronary
heart disease in relatively lean Chinese adults. Int J Cardiol.
2013;168:2141–2145.
32. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and
subcutaneous adipose tissue compartments. Circulation.
2007;116:39–48.
33. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation and insulin
resistance. Gastroenterology. 2007;132:2169–2180.
34. Monteleone P, Fabrazzo M, Martiadis V, et al. Opposite changes in
circulating adiponectin in women with bulimia nervosa or binge
eating disorder. J Clin Endocrinol Metab. 2003;88:5387–5391.
35. Duncan BB, Schmidt MI, Pankow JS, et al., Atherosclerosis Risk in
Communities Study. Low-grade systemic inflammation and the
development of type 2 diabetes. The arteriosclerosis risk in commu-
nities study. Diabetes. 2003;52:1799–1805.
36. Perticone F, Maio R, Sciacqua A, et al. Endothelial dysfunction and
C-reactive protein are risk factors for diabetes in essential hyperten-
sion. Diabetes. 2008;57:167–171.
Medicine  Volume 94, Number 52, December 201537. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation
and prediction of diabetes mellitus in adults (Atherosclerosis Risk in
Communities study): a cohort study. Lancet. 1999;353:1649–1652.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.38. Succurro E, Marini MA, Arturi F, et al. Elevated one-hour post-load
plasma glucose levels identifies subjects with normal glucose
tolerance but early carotid atherosclerosis. Atherosclerosis.
2009;207:245–249.
39. Sesti G, Fiorentino TV, Succurro E, et al. Elevated 1-h post-load
plasma glucose levels in subjects with normal glucose tolerance are
associated with an unfavorable inflammatory profile. Acta Diabetol.
2014;51:927–932.
40. Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between
resistance to insulin-mediated glucose uptake, urinary uric acid
clearance, and plasma uric acid concentration. J Am Med Assoc.
1991;266:3008–3011.
41. Perticone F, Sciacqua A, Perticone M, et al. Serum uric acid and 1-h
postload glucose in essential hypertension. Diabetes Care.
2012;35:153–157.
42. Wolfe BE, Baker CW, Smith AT, et al. Validity and utility of the
current definition of binge eating. Int J Eat Disord. 2009;42:
674–686.
43. Bowen PE, Borthakur G. Postprandial lipid oxidation and cardiovas-
cular disease risk. Curr Atheroscler Rep. 2004;6:477–484.
44. Patel C, Ghanim H, Ravishankar S, et al. Prolonged reactive oxygen
species generation and nuclear factor-kappaB activation after a high-
fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metab.
2007;92:4476–4479.
45. Hudson JI, Lalonde JK, Berry JM, et al. Binge-eating disorder as a
distinct familial phenotype in obese individuals. Arch Gen Psychia-
try. 2006;63:313–319.
46. Bulik CM, Sullivan PF, Kendler KS. Genetic and environmental
contributions to obesity and binge eating. Int J Eat Disord.
Metabolic and Inflammatory Profile in Binge Eating Disorder Obese2003;33:293–298.47. Davis C. The epidemiology and genetics of binge eating disorder
(BED). CNS Spectr. 2015;10:1–8.
www.md-journal.com | 7
